Personal Genome Diagnostics (PGD)

Empowering the fight against cancer by unlocking actionable information from the genome.

Launch date

Nov 2010

Employees

Market cap

Enterprise valuation

€523m (Public information from Dec 2021)

Baltimore Maryland (HQ)

Date	Investors	Amount	Round
-	Small Business Innovation Research (SBIR) Johns Hopkins Technology Ventures	N/A	-
Oct 2010	N/A	$100k	Seed
Aug 2011	N/A	$500k	Seed
Apr 2014	N/A	$2.8m	Angel
Oct 2015	New Enterprise Associates Windham Venture Partners	$21.4m	Series A
Jan 2018	New Enterprise Associates Windham Venture Partners Bristol-Myers Squibb 3B Future Health Fund Maryland Venture Fund	$75.0m	Series B
Oct 2018	Innovatus Capital Partners	N/A	Growth Equity VC
Feb 2021	New Enterprise Associates Windham Venture Partners Sands Capital Management Rock Springs Capital PFM Health Sciences Innovatus Capital Partners Northpond Ventures Vensana Capital Catalio Capital Management Cowen Healthcare Investments Kern Capital	$103m	Series C
Dec 2021*	LabCorp	$575m Valuation: $575m	Acquisition
Total Funding		€184m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Personal Genome Diagnostics (PGD)